Cargando…

Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Fast, Loren, Reagan, John, Quesenberry, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991293/ http://dx.doi.org/10.1186/2051-1426-1-S1-P7

Ejemplares similares

Cellular immunotherapy for refractory hematological malignancies
por: Reagan, John L, et al.
Publicado: (2013)

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia
por: Reagan, J L, et al.
Publicado: (2015)

Next-generation dendritic cells for immunotherapy of acute myeloid leukemia
por: Schnorfeil, Frauke, et al.
Publicado: (2014)

Cell-selective oligonucleotide STAT3 inhibitor for immunotherapy of human acute myeloid leukemia
por: Zhang, Qifang, et al.
Publicado: (2015)

Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
por: Reagan, John L., et al.
Publicado: (2012)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

Calreticulin mediates immune recognition of acute myeloid leukemia cells in vivo
por: Chen, Xiufen, et al.
Publicado: (2013)

Metformin suppresses pediatric acute myeloid leukemia cell viability and clonogenicity
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2014)

Sunitinib effectively reduces clonogenic acute myeloid leukemia cells in vitro
por: Ahmed, Farid, et al.
Publicado: (2014)

Prognostically relevant natural killer cell-mediated immunoediting in acute myeloid leukemia
por: Chan, Christopher J, et al.
Publicado: (2013)

Growth after hematopoietic stem cell transplantation in children with acute myeloid leukemia
por: Chung, Seung Joon, et al.
Publicado: (2013)

A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
por: Uy, Geoffrey, et al.
Publicado: (2014)

P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS
por: Baruchel, André, et al.
Publicado: (2023)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Adoptive cellular therapy using bone marrow-derived T cells for the treatment of childhood leukemia
por: Gershan, Jill, et al.
Publicado: (2015)

Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia
por: Wiatrowski, Kyle, et al.
Publicado: (2022)

P577: EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX
por: Zhang, Jian, et al.
Publicado: (2023)

P69. Targeting naturally presented, leukemia-derived HLA ligands with TCR-transgenic T cells for the treatment of therapy refractory leukemias
por: Richard, K, et al.
Publicado: (2014)

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
por: Fathi, Amir, et al.
Publicado: (2023)

A single nucleotide polymorphism in Wilms’ tumor 1 gene and the risk of acute myeloid leukemia in Sudan
por: Ahmed, Amr A, et al.
Publicado: (2014)

Recombinant trail: a synergistic effect in myeloid leukemias
por: Carvalho, Filipa, et al.
Publicado: (2010)

P1426: WU-NK-101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Muth, J. J., et al.
Publicado: (2022)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

P510: PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY
por: Krüger, Katja, et al.
Publicado: (2023)

P492: SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA
por: Koenig, Kristin, et al.
Publicado: (2023)

Emerging Immunotherapy for Acute Myeloid Leukemia
por: Tabata, Rikako, et al.
Publicado: (2021)

P1302: SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ALSO THE CURATIVE AND SAFE TREATMENT FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN THE ERA OF TARGETED THERAPY
Publicado: (2023)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia
por: Hong, Chang-Sook, et al.
Publicado: (2017)

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
por: Aureli, Anna, et al.
Publicado: (2021)

Immune suppression by myeloid-derived suppressor cells, MDSCs, in MYCN-driven neuroblastoma provides a potential target for cancer immunotherapy
por: Eissler, Nina, et al.
Publicado: (2014)

Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study
por: de Gruijl, Tanja, et al.
Publicado: (2013)

P578: EFFECTIVENESS OF REINDUCTION CHEMOTHERAPY USING BORTEZOMIB WITH HOMOHARRINGTONINE AND CYTARABINE IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA: A PHASE II, MULTICENTER, PROSPECTIVE CLINICAL TRIAL
por: Zhang, Chengtao, et al.
Publicado: (2023)

A novel biomarker assay for cancer immunotherapy development based on myeloid derived supressor cells (MDSCs)
por: Hepburne-Scott, Henry
Publicado: (2013)

Development of a personalized cellular ex-vivo cbl-b silencing cancer immunotherapy
por: Lametschwandtner, Guenther, et al.
Publicado: (2014)

Treatment of refractory juvenile dermatomyositis with tacrolimus
por: Hassan, J, et al.
Publicado: (2008)

P494: A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA
por: Selwyn Stein, Anthony, et al.
Publicado: (2023)

Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress
por: Chergui, Adel, et al.
Publicado: (2023)

Recent developments in immunotherapy of acute myeloid leukemia
por: Lichtenegger, Felix S., et al.
Publicado: (2017)

The Important Role of Immunotherapies in Acute Myeloid Leukemia
por: Greiner, Jochen
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gs9hmpcsf4tkocqcdbbd6ic8la